Analyzing Tandem Diabetes Care (NASDAQ:TNDM) and Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Earnings & Valuation

This table compares Vivos Therapeutics and Tandem Diabetes Care”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vivos Therapeutics $17.44 million 0.09 -$21.17 million ($1.90) -0.04
Tandem Diabetes Care $1.01 billion 1.27 -$204.71 million ($0.72) -25.67

Vivos Therapeutics has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vivos Therapeutics and Tandem Diabetes Care, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivos Therapeutics 1 1 2 0 2.25
Tandem Diabetes Care 1 12 9 1 2.43

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 3,306.33%. Tandem Diabetes Care has a consensus target price of $27.18, indicating a potential upside of 47.10%. Given Vivos Therapeutics’ higher possible upside, research analysts plainly believe Vivos Therapeutics is more favorable than Tandem Diabetes Care.

Insider and Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. 1.4% of Vivos Therapeutics shares are held by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Vivos Therapeutics has a beta of 6.37, suggesting that its stock price is 537% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Vivos Therapeutics and Tandem Diabetes Care’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vivos Therapeutics -122.00% -2,325.64% -102.01%
Tandem Diabetes Care -4.58% -35.61% -4.53%

Summary

Tandem Diabetes Care beats Vivos Therapeutics on 10 of the 15 factors compared between the two stocks.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics is a medical technology company focused on treatments for sleep-disordered breathing, including obstructive sleep apnea. The company works with dental providers to offer non-surgical approaches intended to improve patients’ airways and breathing during sleep. Its Vivos System combines proprietary oral appliances with treatment protocols used by trained dental professionals. The company also provides education and support to providers who offer its therapies. Based in Littleton, Colorado, Vivos primarily serves patients through a network of participating dental practices.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.